Proactive Investors - Run By Investors For Investors

Frontier IP ticks up as Exscientia signs collaboration deal with Chinese biotech firm

As part of the partnership, Exscientia was entitled to become a GT Apeiron shareholder and receive milestone payments and royalties based on the clinical and commercial success of its drug discovery programmes
Drugs
GT Apeiron was launched by private equity firm GT Healthcare, which is also an Exscientia investor

Frontier IP Group PLC’s (LON:FIPP) shares ticked up on Friday after its portfolio firm Exscientia entered a drug discovery collaboration with Shanghai-based biotech firm GT Apeiron Therapeutics.

The AIM-listed firm, which commercialises intellectual property, said as part of the partnership Exscientia was entitled to become a GT Apeiron shareholder and receive milestone payments and royalties based on the clinical and commercial success of its drug discovery programmes.

READ: Frontier IP’s Fieldwork Robotics sees success in initial trials of fruit-picking robot

GT Apeiron was launched by GT Healthcare Capital Partners (GTH), a life science-focused private equity partnership, with US$27mln of financial backing.

GTH is also an investor in Exscientia having participated in a US$26mln funding round previously.

Professor Andrew Hopkins, Exscientia's chief executive, said medicines generated by the collaboration would focus on areas of “significant unmet need with global potential”.

"This is an exciting time for pharmaceutical research, with innovative approaches to drug discovery as well as the development of new commercial markets. Both are strongly evident in China, already the second largest national pharmaceutical market in the world, where we are delighted to join our expertise and technology with GT Apeiron to initiate our first discovery opportunity in the country”, the CEO added.

Frontier holds a 3.32% stake in Exscientia.

The shares were up 0.6% at 79p in early deals.

--Adds share price--

View full FIPP profile View Profile

Frontier IP Group PLC Timeline

Related Articles

Online payment
June 12 2019
The company's payment services specialise in card-not-present transactions, payments made without face-to-face contact or verification, usually online or via mobile
Interviewees
August 07 2018
The offer values Nash at £98.7mln and DBAY already controls 26.1% of Harvey Nash shares
drone
March 29 2019
RMS is taking action to address the issues at Geocurve and looks forward to “renewed growth in sales to new clients” while it remains "excited by the opportunities at GyroMetric"

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use